142 results about "Nerve growth factor" patented technology

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention discloses a collagen-based and high-transparency matrix for cornea thickening and a preparation method of the collagen-based and high-transparency matrix. The preparation method comprises the following steps: assembling a collagen composite solution into a collagen matrix implant on a set curvature mold through electrochemical deposition; the collagen composite solution is prepared from collagen, glacial acetic acid, hydrogen peroxide, heparin and water; putting the obtained collagen matrix implant and a mold into a cross-linking agent solution for cross-linking; cleaning the residual cross-linking agent after completion, separating the collagen matrix implant from the mold, and placing the collagen matrix implant under an ultraviolet light source for cross-linking to obtain a double-cross-linked collagen matrix implant; and soaking the double-crosslinked collagen matrix implant in a nerve growth factor solution, and performing absorption and combination to obtain the collagen-based and high-transparency matrix for cornea thickening. According to the invention, an electro-deposition assembly technical scheme is adopted, the diameter and thickness of collagen assembly fibers are adjusted and controlled through electric field energy, and the collagen assembly fibers are orderly and regularly arranged, so that scattering and refraction of light are reduced, the light transmittance of cornea is increased and can reach more than 90%, and the problem of light blocking caused by materials is effectively avoided. Operation is matched with femtosecond equipment, operation is easy, consumed time is short, and trauma is small.

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The invention discloses a neural microelectrode for electrical stimulation combined with drug release and a preparation method thereof.The neural microelectrode comprises a first flexible substrate layer, a drug-loaded slow-release layer, a second flexible substrate layer, a conductive layer and an insulating covering layer, and the drug-loaded slow-release layer contains chitosan microspheres embedded with drugs; the medicament comprises nerve growth factors and / or anti-inflammatory drugs, a plurality of drug release holes are distributed in the insulating covering layer, an electrode contact is arranged at one end of the conducting layer, a lead connector is electrically arranged at the other end of the conducting layer, and openings for exposing the electrode contact and the lead connector are correspondingly formed in the two ends of the insulating covering layer respectively. According to the neural microelectrode provided by the invention, the drug-loaded slow-release layer is integrated in the neural microelectrode, so that a space for storing a drug does not need to be additionally processed on the membrane layer, and the drug does not need to be additionally loaded, so that the production and processing are relatively convenient and rapid; after the neural microelectrode is implanted into a corresponding tissue in a body, the drug-loaded sustained-release layer can be gradually degraded to slowly release a medicament for repairing nervous tissues or avoiding rejection reaction in a long-acting manner.

The present invention relates to the application of a silymarin pharmaceutical composition in the preparation of a drug for treating fatty liver disease, and belongs to the field of medical technology. The present invention provides the application of a pharmaceutical composition in the preparation of a drug for preventing and / or treating fatty liver disease, wherein the active ingredient of the pharmaceutical composition comprises a 7-KDCA regulator; the 7-KDCA regulator comprises silymarin, or the 7-KDCA regulator comprises silybin, silybin, silybinin and / or isosilybin; the silybin comprises silybin A and / or silybin B; the isosilybin comprises isosilybin A and / or isosilybin B. Studies have shown that the pharmaceutical composition can effectively and safely treat fatty liver disease at a low dose, has anti-inflammatory activity, and has a mimetic nerve growth factor activity, and has great application prospects in the preparation of drugs for preventing and / or treating fatty liver disease, anti-inflammatory, and preventing and / or treating Alzheimer's disease.

A liquid pharmaceutical formulation, suitable for lyophilization, comprising nerve growth factor (NGF) and at least one pharmaceutically acceptable excipient.

The present disclosure generally relates to novel chimeric antigen receptors (“CARs”), modified regulatory T cells (“Tregs”) expressing such CARs and / or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative / inflammatory activity, or which promote neuronal growth / survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and / or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.

The invention discloses a composition containing a recombinant human nerve growth factor, application of the composition and an ophthalmic preparation. The composition is prepared from the following components in parts by weight: 0.005 to 1 part of recombinant human nerve growth factor, 20 to 70 parts of trehalose, 5 to 30 parts of mannitol and 1 to 13 parts of polyvinyl alcohol. The trehalose, the mannitol and the polyvinyl alcohol are compounded with the recombinant human nerve growth factor, so that the stability of the recombinant human nerve growth factor can be remarkably improved, and the loss of pharmacological active ingredients of the ophthalmic preparation in the preparation, transportation and long-term storage periods is reduced, so that the medication safety and the treatment effect are ensured; and the recombinant human nerve growth factor in the ophthalmic preparation is good in stability, so that the clinical requirements of patients with eye diseases can be better met.

The invention relates to the technical field of gene engineering, in particular to construction and application of a fusion gene for coding a green fluorescence labeled nerve growth factor fusion protein with biological activity. The nucleotide sequence of the fusion gene and the amino acid sequence of the fusion protein are respectively shown as SEQ ID No.1 and SEQ ID No.2. The invention also relates to methods for constructing an expression plasmid containing the nucleotide sequence of the fusion gene, preparing a virus vector and the like. The fusion gene can be expressed into a nerve growth factor fusion protein with green fluorescence in cells cultured in vitro and animal bodies, so that the expression and distribution of the fusion gene in the cells and tissues can be directly observed under a fluorescence microscope, and the fusion protein still has the biological activity of the nerve growth factor. The nerve growth factor in the fusion protein can be accurately metered by measuring the fluorescence intensity of the fusion protein or the content of the fusion protein.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The present disclosure relates to a biomarker for distinguishing between depression and bipolar disorder and uses thereof, elucidating a composition for distinguishing between depression and bipolar disorders and a method for providing information for distinguishing between depression and bipolar disorder, using same, wherein the composition is based on a biomarker composition comprising eotaxin, nerve growth factors (NGF), tumor necrosis factor-α (TNF-α), glial cell derived neurotrophic factor (GDNF), interleukin-1β (IL-1β), and serum soluble CD40 Ligand (sCD40L) within a serum sample and includes an agent for measuring the expression level of each of the six biomarker proteins.

The present disclosure relates to an antigen-binding molecule that specifically binds to nerve growth factor (NGF) and uses thereof.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The invention discloses a macrocyclic trichothene compound with a neuroprotective activity effect as well as a preparation method and application of the macrocyclic trichothene compound. According to the macrocyclic trichothene compound, a new compound Epiroridine acid A is prepared by separating a secondary metabolite derived from a fungus Myrothecium roridine; a cellular level experiment proves that the prepared Epiridine acid A can stimulate a stably transfected cell strain (NGF-293T) of a nerve growth factor to highly express an NGF gene, and can be used for preparing a medicine for neuroprotective treatment.

The present application relates to a kind of water gel support prepared by self-assembled polypeptide and the use of support obtained therefrom, the preparation method includes: 1) self-assembled peptide sequence is linked nerve growth factor analog peptide by covalent bond to obtain bonded functional polypeptide;2) macrophage is separated and cultured, and is induced to be " alternative activation " anti-inflammatory M2 macrophage, obtain culture supernatant and carry out filtration, obtain filtered cell culture supernatant;3) filtered cell culture supernatant is mixed with bonded functional polypeptide, obtain mixed solution and adjust the concentration of the mixed solution, the bonded functional polypeptide self-assembles and forms water gel support.The present application uses M2 macrophage condition culture supernatant to construct regenerative microenvironment, combines polypeptide functional water gel support, realizes better overall interaction, and prepares the water gel support that can supplement and regulate nerve regeneration, the support can promote nerve cell regeneration behavior, provides new selection for tissue engineering biomaterials.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The invention provides a cleaning and preserving fluid for fetal brain tissues and a preserving method thereof, and belongs to the technical field of tissue preservation. The cleaning and preserving fluid comprises trehalose, nerve growth factors, a GlutaMAX supplement, Y27632, S-nitrosoglutathione, tert-butylhydroquinone, a Versene solution and polyvinylpyrrolidone, compared with a traditional tissue preserving fluid, the cleaning and preserving fluid not only can improve the purity of neural stem cells, but also can maintain the activity and the yield of the neural stem cells in fetal brain tissue, and the cleaning and preserving fluid has the advantages that the cleaning and preserving fluid is simple in structure and convenient to use. The structural integrity of the cells is guaranteed, a high-quality sample is provided for subsequent research on proliferation, differentiation and the like of the neural stem cells, and the method has a wide application prospect.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The present invention relates to Nerve growth factor (NGF) or a mutein thereof, for use in the treatment of Niemann-Pick type C in a subject.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Provided is a recombinant protein, which contains a nerve growth factor (NGF) protein variant and a heterologous signal peptide linked to the NGF protein variant. Further provided are a combination containing an mRNA encoding the recombinant protein and a delivery vector, and the use thereof in the treatment of toxic / hereditary / metabolic peripheral neuropathy, nerve regeneration repair, and / or central nervous system degenerative diseases.

The invention discloses a whitening and anti-aging mask formula based on dogwood. The whitening and anti-aging mask formula based on dogwood is prepared from the following raw materials in parts by mass: 5 to 15 parts of dogwood extract, 2 to 8 parts of vitamin C powder, 1 to 3 parts of polyphenol compound, 1 to 5 parts of glycerinum, 2 to 4 parts of hyaluronic acid, 3 to 9 parts of plant essence, 2 to 6 parts of vegetable oil, 4 to 12 parts of seaweed extract and 1 to 3 parts of polyether-201. 1-3 parts of nerve growth factors, 2-6 parts of DNA (deoxyribonucleic acid) repair enzyme, 0.1-0.3 part of snake venom essence, 1-3 parts of plant stem cells and 20-30 parts of deionized water, components in the snake venom essence can stimulate synthesis of collagen and increase skin elasticity, so that wrinkles and fine wrinkles are reduced, the skin looks younger and tighter, certain antioxidant capacity is achieved, and the skin care effect is good. Free radicals can be neutralized, the damage of environmental pollution and ultraviolet radiation to the skin is reduced, and the aging process of the skin is delayed.

The present invention belongs to the technical field of biomedicine, and specifically relates to a nociceptor skin organoid chip and its culture medium, construction method and application. A culture medium for a nociceptor skin organoid chip, the culture medium is composed of fetal bovine serum and the following components added to the fetal bovine serum: epidermal growth factor, bovine pituitary extract, Normocin, B27, nerve growth factor, insulin, hydrocortisone, human brain-derived neurotrophic factor and capsaicin. Using this culture medium to co-culture a skin chip with nociceptors to obtain a nociceptor skin organoid chip, which can be used for the verification of pain perception effects.

Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

The invention provides multifunctional hydrogel carrying neural stem cells. The multifunctional hydrogel mainly comprises the following components: chitosan, beta-sodium glycerophosphate, edaravone, nerve growth factors and the neural stem cells, the invention also provides a method for preparing the multifunctional hydrogel, which comprises the following steps: preparing temperature-sensitive hydrogel by taking a chitosan solution and a beta-sodium glycerophosphate solution as matrixes, preparing an edaravone-nerve growth factor mixed solution, and preparing the edaravone-nerve growth factor composite hydrogel. Sequentially adding a neural stem cell suspension and the mixed solution into a hydrogel system to obtain the multifunctional hydrogel carrying the neural stem cells. The multifunctional hydrogel disclosed by the invention realizes high-efficiency integration of three core functions of temperature-sensitive positioning, drug sustained-release microenvironment regulation and control and cell proliferation and differentiation support, and can remarkably promote spinal cord injury repair.

The invention discloses a spinal cord injury repair multifunctional composite material and a preparation method and application thereof. The material is prepared from chitosan-loaded nano manganese dioxide, resveratrol and nerve growth factors. The method comprises the following steps: adding a dispersing agent and modified nano-manganese dioxide into a chitosan solution, and then adding a resveratrol solution and a diluted nerve growth factor solution into the chitosan solution to obtain a mixed solution; finally, the mixed solution is subjected to freeze drying treatment, and the spinal cord injury repairing multifunctional composite material is obtained. The spinal cord injury repair multifunctional composite material can be used as a medical stent material for treating spinal cord injury. Through the innovation of drug controlled release (pH response + slow release) and multi-mechanism cooperation (oxidation resistance / inflammation resistance / regeneration), the limitation of a single mode of spinal cord injury treatment is broken through, and a comprehensive strategy with a wide application prospect is provided for SCI repair.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and / or reduced nociceptive activity, compared to wildtype human NGF.